Clinical Trials Logo

Breast Adenocarcinoma clinical trials

View clinical trials related to Breast Adenocarcinoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05579366 Recruiting - Ovarian Cancer Clinical Trials

PRO1184 for Advanced Solid Tumors

PRO1184-001
Start date: December 7, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1184 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

NCT ID: NCT05447910 Recruiting - Clinical trials for Invasive Breast Carcinoma

Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer

Start date: July 21, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial examines letrozole in patients with newly diagnosed hormone receptor-positive HER2-negative invasive breast cancer that can be removed by surgery (operable). Letrozole is in a class of medications called nonsteroidal aromatase inhibitors. It works by decreasing the amount of estrogen produced by the body. This can slow or stop the growth of some types of breast cancer cells that need estrogen to grow.

NCT ID: NCT05183828 Recruiting - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

Start date: January 23, 2022
Phase: Phase 4
Study type: Interventional

This stage IV trial examines how a mutation in HSD3B1 (1245C) gene affects treatment of stage I-III breast cancer. This trial may help researchers determine if mutations in HSD3B1 decreases the efficacy of aromatase inhibitor therapy such as letrozole. Letrozole may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT04517838 Recruiting - Clinical trials for Breast Adenocarcinoma

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

Start date: July 27, 2020
Phase:
Study type: Observational

This study gathers information from the blood cells and tumor tissue during treatment with anti-HER2 therapies, such as trastuzumab, pertuzumab, lapatinib, or neratinib, in patients with HER2 positive stage I-IV breast cancer who are scheduled to start anti-HER2 therapy. The information gained from this study may help researchers better understand the relation between cell response and anti-HER2 therapies.

NCT ID: NCT04300829 Recruiting - Radiation Toxicity Clinical Trials

Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients

CICA-RT
Start date: June 6, 2020
Phase: Phase 3
Study type: Interventional

Phase III, prospective, interventional, multicentric, comparative, randomized, open study with 2 parallel arms, evaluating the efficacy of Cicaderma ointment vs standard management of each site in preventing the onset of grade > 2 radiodermatitis according to the National Cancer Institute - Common Terminology Criteria for Adverse Events-Version (NCI-CTCAE-V5)

NCT ID: NCT04197687 Recruiting - Clinical trials for Stage IIIC Breast Cancer AJCC v7

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Start date: February 20, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has residual disease after chemotherapy prior to surgery. It also studies why some HER2 positive breast cancer patients respond better to chemotherapy in combination with trastuzumab and pertuzumab. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim increases the number of white blood cells in the body following chemotherapy for certain types of cancer and is used to alert the immune system. It is not yet known if TPIV100 and sargramostim will work better in treating patients with HER2 positive, stage II-III breast cancer.